Laboratory Medicine ›› 2023, Vol. 38 ›› Issue (10): 951-956.DOI: 10.3969/j.issn.1673-8640.2023.10.009
Previous Articles Next Articles
DUAN Yong1, WANG Yong1, ZHANG Yumin1, ZENG Haitao1, LIU Qing2()
Received:
2022-11-22
Revised:
2023-02-19
Online:
2023-10-30
Published:
2023-12-18
CLC Number:
DUAN Yong, WANG Yong, ZHANG Yumin, ZENG Haitao, LIU Qing. Predictive value of red blood cell distribution width for in-hospital mortality in ICU patients with heart failure:a retrospective study based on the MIMIC-Ⅲ database[J]. Laboratory Medicine, 2023, 38(10): 951-956.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2023.10.009
变量 | 单因素分析 | 多因素分析 | |||||
---|---|---|---|---|---|---|---|
OR值 | 95%CI | P值 | OR值 | 95%CI | P值 | ||
RDW | 1.373 | 1.173~1.608 | <0.001 | 1.578 | 1.019~2.445 | 0.041 | |
性别 | |||||||
女性 | 参照 | ||||||
男性 | 0.878 | 0.628~1.226 | 0.444 | ||||
入住ICU类型 | |||||||
心内科ICU | 参照 | ||||||
内科ICU | 2.266 | 1.373~3.740 | 0.001 | 2.051 | 1.129~3.596 | 0.018 | |
外科ICU | 2.294 | 1.152~4.569 | 0.018 | 2.599 | 1.180~5.721 | 0.018 | |
心脏外科ICU | 1.541 | 0.622~3.819 | 0.350 | 1.143 | 0.420~3.113 | 0.793 | |
创伤外科ICU | 3.369 | 1.503~7.542 | 0.003 | 3.256 | 1.305~8.121 | 0.011 | |
种族 | |||||||
其他 | 参照 | ||||||
非裔 | 2.035 | 1.101~3.760 | 0.023 | 2.595 | 1.256~5.326 | 0.010 | |
血管活性药物 | |||||||
未使用 | 参照 | ||||||
使用 | 0.179 | 0.124~0.259 | <0.001 | 2.714 | 1.717~4.290 | <0.001 | |
呼吸机 | |||||||
未使用 | 参照 | ||||||
使用 | 0.487 | 0.347~0.684 | <0.001 | 1.414 | 0.923~2.166 | 0.111 | |
SOFA评分 | 1.246 | 1.195~1.336 | <0.001 | 1.045 | 0.973~1.123 | 0.226 | |
GWTG-HF | 1.028 | 1.017~1.039 | <0.001 | 1.016 | 1.002~1.030 | 0.025 | |
ECI评分 | 1.058 | 1.044~1.072 | <0.001 | 1.035 | 1.019~1.051 | <0.001 | |
体重指数 | 0.976 | 0.951~1.000 | 0.054 | ||||
舒张压 | 0.975 | 0.959~0.991 | 0.003 | 0.999 | 0.978~1.021 | 0.610 | |
红细胞 | 0.891 | 0.677~1.171 | 0.407 | ||||
血红蛋白 | 0.912 | 0.823~1.011 | 0.080 | ||||
血糖 | 1.002 | 0.999~1.005 | 0.270 | ||||
凝血酶原时间 | 1.044 | 1.025~1.064 | <0.001 | 1.020 | 0.997~1.044 | 0.096 | |
NT-proBNP | 1.000 | 1.000~1.000 | 0.260 | 1.000 | 1.000~1.000 | 0.039 | |
乳酸 | 1.699 | 1.452~1.988 | <0.001 | 1.547 | 1.290~1.855 | <0.001 | |
LVEF | 0.995 | 0.982~1.007 | 0.405 | ||||
住院时间 | 1.064 | 1.042~1.086 | <0.001 | 1.028 | 1.003~1.053 | 0.031 |
变量 | 单因素分析 | 多因素分析 | |||||
---|---|---|---|---|---|---|---|
OR值 | 95%CI | P值 | OR值 | 95%CI | P值 | ||
RDW | 1.373 | 1.173~1.608 | <0.001 | 1.578 | 1.019~2.445 | 0.041 | |
性别 | |||||||
女性 | 参照 | ||||||
男性 | 0.878 | 0.628~1.226 | 0.444 | ||||
入住ICU类型 | |||||||
心内科ICU | 参照 | ||||||
内科ICU | 2.266 | 1.373~3.740 | 0.001 | 2.051 | 1.129~3.596 | 0.018 | |
外科ICU | 2.294 | 1.152~4.569 | 0.018 | 2.599 | 1.180~5.721 | 0.018 | |
心脏外科ICU | 1.541 | 0.622~3.819 | 0.350 | 1.143 | 0.420~3.113 | 0.793 | |
创伤外科ICU | 3.369 | 1.503~7.542 | 0.003 | 3.256 | 1.305~8.121 | 0.011 | |
种族 | |||||||
其他 | 参照 | ||||||
非裔 | 2.035 | 1.101~3.760 | 0.023 | 2.595 | 1.256~5.326 | 0.010 | |
血管活性药物 | |||||||
未使用 | 参照 | ||||||
使用 | 0.179 | 0.124~0.259 | <0.001 | 2.714 | 1.717~4.290 | <0.001 | |
呼吸机 | |||||||
未使用 | 参照 | ||||||
使用 | 0.487 | 0.347~0.684 | <0.001 | 1.414 | 0.923~2.166 | 0.111 | |
SOFA评分 | 1.246 | 1.195~1.336 | <0.001 | 1.045 | 0.973~1.123 | 0.226 | |
GWTG-HF | 1.028 | 1.017~1.039 | <0.001 | 1.016 | 1.002~1.030 | 0.025 | |
ECI评分 | 1.058 | 1.044~1.072 | <0.001 | 1.035 | 1.019~1.051 | <0.001 | |
体重指数 | 0.976 | 0.951~1.000 | 0.054 | ||||
舒张压 | 0.975 | 0.959~0.991 | 0.003 | 0.999 | 0.978~1.021 | 0.610 | |
红细胞 | 0.891 | 0.677~1.171 | 0.407 | ||||
血红蛋白 | 0.912 | 0.823~1.011 | 0.080 | ||||
血糖 | 1.002 | 0.999~1.005 | 0.270 | ||||
凝血酶原时间 | 1.044 | 1.025~1.064 | <0.001 | 1.020 | 0.997~1.044 | 0.096 | |
NT-proBNP | 1.000 | 1.000~1.000 | 0.260 | 1.000 | 1.000~1.000 | 0.039 | |
乳酸 | 1.699 | 1.452~1.988 | <0.001 | 1.547 | 1.290~1.855 | <0.001 | |
LVEF | 0.995 | 0.982~1.007 | 0.405 | ||||
住院时间 | 1.064 | 1.042~1.086 | <0.001 | 1.028 | 1.003~1.053 | 0.031 |
[1] |
SAFAVI K C, DHARMARAJAN K, KIM N, et al. Variation exists in rates of admission to intensive care units for heart failure patients across hospitals in the United States[J]. Circulation, 2013, 127(8):923-929.
DOI PMID |
[2] |
ADAMS K F Jr, FONAROW G C, EMERMAN C L, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States:rationale,design,and preliminary observations from the first 100 000 cases in the Acute Decompensated Heart Failure National Registry(ADHERE)[J]. Am Heart J, 2005, 149(2):209-216.
DOI URL |
[3] |
OZGUL G, SEYHAN E C, ÖZGÜL M A, et al. Red blood cell distribution width in patients with chronic obstructive pulmonary disease and healthy subjects[J]. Archivos De Bronconeumologia, 2017, 53(3):107-113.
DOI URL |
[4] |
XANTHOPOULOS A, GIAMOUZIS G, MELIDONIS A, et al. Red blood cell distribution width as a prognostic marker in patients with heart failure and diabetes mellitus[J]. Cardiovascular diabetology, 2017, 16(1):81.
DOI PMID |
[5] | LI N, ZHOU H, TANG Q. Red blood cell distribution width:a novel predictive indicator for cardiovascular and cerebrovascular diseases[J]. Disease markers, 2017, 2017:7089493. |
[6] |
SALVATORI M, FORMIGA F, MORENO-GÓNZALEZ R, et al. Red blood cell distribution width as a prognostic factor of mortality in elderly patients firstly hospitalized due to heart failure[J]. Kardiol Pol, 2019, 77(6):632-638.
DOI PMID |
[7] |
WOOWIEC, ROGOWICZ D, BANACH J, et al. Prognostic significance of red cell distribution width and other red cell parameters in patients with chronic heart failure during two years of follow-up[J]. Kardiol Pol, 2016, 74(7):657-664.
DOI PMID |
[8] |
TRUBY L K, SRIDHARAN L, FLORES R J, et al. Red cell distribution width predicts 90 day mortality in continuous-flow left ventricular assist device patients[J]. ASAIO J, 2019, 65(3):233-240.
DOI PMID |
[9] | PENG Y, GUAN X, WANG J, et al. Red cell distribution width is correlated with all-cause mortality of patients in the coronary care unit[J]. J Int Med Res, 2020, 48(7):300060520941317. |
[10] |
SOTIROPOULOS K, YERLY P, MONNEY P, et al. Red cell distribution width and mortality in acute heart failure patients with preserved and reduced ejection fraction[J]. ESC Heart Fail, 2016, 3(3):198-204.
DOI PMID |
[11] |
IMAI R, UEMURA Y, OKUMURA T, et al. Impact of red blood cell distribution width on non-cardiac mortality in patients with acute decompensated heart failure with preserved ejection fraction[J]. J Cardiol, 2017, 70(6):591-597.
DOI PMID |
[12] |
PETERSON P N, RUMSFELD J S, LIANG L, et al. A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association get with the guidelines program[J]. Circulation Cardiovascular Quality and Outcomes, 2010, 3(1):25-32.
DOI URL |
[13] |
WIN S, HUSSAIN I, HEBL V B, et al. Inpatient mortality risk scores and postdischarge events in hospitalized heart failure patients:a community-based study[J]. Circulation Heart failure, 2017, 10(7):e003926.
DOI URL |
[14] |
SUZUKI S, YOSHIHISA A, SATO Y, et al. Clinical significance of get with the guidelines-heart failure risk score in patients with chronic heart failure after hospitalization[J]. Journal of the American Heart Association, 2018, 7(17):e008316.
DOI URL |
[15] |
LYLE M, WAN S H, MURPHREE D, et al. Predictive value of the get with the guidelines heart failure risk score in unselected cardiac intensive care unit patients[J]. J Am Heart Assoc, 2020, 9(3):e012439.
DOI URL |
[16] |
FÖRHÉCZ Z, GOMBOS T, BORGULYA G, et al. Red cell distribution width in heart failure:prediction of clinical events and relationship with markers of ineffective erythropoiesis,inflammation,renal function,and nutritional state[J]. Am Heart J, 2009, 158(4):659-666.
DOI URL |
[17] |
WAN J, RISTENPART W D, STONE H A. Dynamics of shear-induced ATP release from red blood cells[J]. Proc Natl Acad Sci U S A, 2008, 105(43):16432-16437.
DOI URL |
[18] |
IVERSEN P O, WOLDBAEK P R, TØNNESSEN T, et al. Decreased hematopoiesis in bone marrow of mice with congestive heart failure[J]. Am J Physiol Regul Integr Comp Physiol, 2002, 282(1):R166-R172.
DOI URL |
[19] |
ANAND I S, GUPTA P. Anemia and iron deficiency in heart failure:current concepts and emerging therapies[J]. Circulation, 2018, 138(1):80-98.
DOI URL |
[20] |
BOGDAN C. Oxidative burst without phagocytes:the role of respiratory proteins[J]. Nat Immunol, 2007, 8(10):1029-1031.
DOI |
[21] |
KERCHBERGER V E, WARE L B. The role of circulating cell-free hemoglobin in sepsis-associated acute kidney injury[J]. Semin Nephrol, 2020, 40(2):148-159.
DOI PMID |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||